EPS-producing Leuconostoc as probiotics: biomedical potential and structure–function perspectives
- 1Institute of Biochemistry and Biophysics, Polish Academy of Sciences
- 2Doctoral School of Molecular Biology and Biological Chemistry
Abstract
With the increasing prevalence of diseases associated with gut dysbiosis, such as gastrointestinal diseases, immunological disorders, metabolic and cardiovascular diseases, and cancer, there is a growing need for effective strategies to restore the gut microbiota and promote overall health. In this context, underexplored lactic acid bacteria, particularly those capable of producing exopolysaccharides (EPSs), are gaining attention due to the diverse and pleiotropic health benefits of their EPSs. This narrative review provides an overview of the health-promoting properties of Leuconostoc species and their associated EPSs, with particular emphasis on the structure–function relationships underlying EPS bioactivity. Furthermore, it examines the mechanisms through which EPS-producing Leuconostoc strains may influence gut and systemic health and discusses their potential as next-generation microbiome-based interventions. Notably, most available evidence is derived from in vitro and other preclinical models, while clinical studies directly validating the efficacy and health benefits of Leuconostoc EPSs in humans remain limited.
Related
- Whole genome sequences of four potential indigenous probiotics strains isolated from sediment of Sundarbans mangrove and wild black tiger shrimp (Penaeus monodon) from the Bay of Bengal, Bangladesh
- The Screening and Identification of Potential Probiotics in Misgurnus anguillicaudatus Intestine
- Complete genome sequence of Enterococcus faecium strain GB_C_05 with potential characteristics applicable as a bacteriocin-producing probiotic feed additive.
- Producing biogas from energy cover crops in France: Potential production and agro-environmental impacts
- Unveiling the potential of two different lactococcal glutamate decarboxylase enzymes and their application for producing GABA-rich soy beverages
BibTeX
@article{kopczynska2026epsproducing,
title = {{EPS-producing Leuconostoc as probiotics: biomedical potential and structure–function perspectives}},
author = {Julia Kopczyńska and Olha Kostiuchenko and Magdalena Kowalczyk},
journal = {Frontiers in Microbiology},
year = {2026},
month = nov,
doi = {10.3389/fmicb.2026.1912100},
url = {https://www.frontiersin.org/articles/10.3389/fmicb.2026.1912100/full},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - EPS-producing Leuconostoc as probiotics: biomedical potential and structure–function perspectives
AU - Julia Kopczyńska
AU - Olha Kostiuchenko
AU - Magdalena Kowalczyk
PY - 2026
DA - 2026/11/10
JO - Frontiers in Microbiology
DO - 10.3389/fmicb.2026.1912100
UR - https://www.frontiersin.org/articles/10.3389/fmicb.2026.1912100/full
AB - With the increasing prevalence of diseases associated with gut dysbiosis, such as gastrointestinal diseases, immunological disorders, metabolic and cardiovascular diseases, and cancer, there is a growing need for effective strategies to restore the gut microbiota and promote overall health. In this context, underexplored lactic acid bacteria, particularly those capable of producing exopolysaccharides (EPSs), are gaining attention due to the diverse and pleiotropic health benefits of their EPSs. This narrative review provides an overview of the health-promoting properties of Leuconostoc species and their associated EPSs, with particular emphasis on the structure–function relationships underlying EPS bioactivity. Furthermore, it examines the mechanisms through which EPS-producing Leuconostoc strains may influence gut and systemic health and discusses their potential as next-generation microbiome-based interventions. Notably, most available evidence is derived from in vitro and other preclinical models, while clinical studies directly validating the efficacy and health benefits of Leuconostoc EPSs in humans remain limited.
SN - 1664-302X
ER -